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ABSTRACT
Autoantibodies refer to antibodies that target self-
antigens, which can play pivotal roles in maintain-
ing homeostasis, distinguishing normal from tumor
tissue and trigger autoimmune diseases. In the last
three decades, tremendous efforts have been de-
voted to elucidate the generation, evolution and func-
tions of autoantibodies, as well as their target au-
toantigens. However, reports of these countless pre-
viously identified autoantigens are randomly dis-
persed in the literature. Here, we constructed an AA-
gAtlas database 1.0 using text-mining and manual
curation. We extracted 45 830 autoantigen-related ab-
stracts and 94 313 sentences from PubMed using the
keywords of either ‘autoantigen’ or ‘autoantibody’ or
their lexical variants, which were further refined to 25
520 abstracts, 43 253 sentences and 3984 candidates
by our bio-entity recognizer based on the Protein On-
tology. Finally, we identified 1126 genes as human
autoantigens and 1071 related human diseases, with
which we constructed a human autoantigen database
(AAgAtlas database 1.0). The database provides a
user-friendly interface to conveniently browse, re-
trieve and download human autoantigens as well as
their associated diseases. The database is freely ac-
cessible at http://biokb.ncpsb.org/aagatlas/. We be-
lieve this database will be a valuable resource to track
and understand human autoantigens as well as to
investigate their functions in basic and translational
research.
INTRODUCTION
Autoantibodies (AAb) are antibodies that bind to individ-
ual’s own antigens. Their production can be affected by ge-
netic predisposition, environment, viruses and pathogens
(via epitope mimicking) and chemicals, etc. In the last three
decades numerous studies have been devoted to elucidating
the generation, evolution and functions of AAbs as well as
their target autoantigens (AAgs) (Figure 1) (1–3).The accu-
mulating evidence indicates that AAbs play pivotal roles in
maintaining homeostasis of healthy individuals and cancer
patients through auto-clearance of aged cells and dysfunc-
tional dividing cells, respectively (2,4). Moreover, disorders
of the immune system may lead to autoimmune diseases.
Multiple AAbs that are specific to autoimmune disease have
been found, including thyroiditis, type 1 diabetes mellitus
and primary biliary cirrhosis, indicating the contribution of
AAbs to pathology by inflammatory stimulation (5–7).
Circulating AAbs can serve as biomarkers for the early
diagnostics, prognosis and therapeutic treatment of human
diseases (8–11). For example, an AAg biomarker panel
(p53, NY-ESO-1, CAGE, GBU4-5, Annexin1 and SOX2),
called EarlyCDT®Lung test, has been approved by FDA
for the early detection of lung cancer in high risk and
asymptomatic patients prior to standard CT imaging test.
The panel showed sensitivity and specificity of 46% (12/26)
and 83% (599/726) for the early stage of lung cancer (12).
Using protein microarrays with 4988 human proteins, An-
derson et al. found a panel of 28 AAgs for the detection of
early stage breast cancer with sensitivity of 80.8% and speci-
ficity of 61.6%, respectively (10). These AAbs have been in-
tegrated with several protein biomarkers and become the
first protein-based blood test, Videssa® Breast, provided
by Provista Diagnostics for early breast cancer detection
(13). Using bead-based arrays, Ayoglu et al. profiled the sera
from multiple sclerosis patients with 11 520 proteins and
identifiedAnoctamin 2 as an autoimmune target inmultiple
sclerosis (14). In addition, some tumor AAgs might be ideal
targets for targeted immunotherapy such as p53, HER2
and NY-ESO-1 (15,16). For example, HER2 is highly ex-
pressed on the surface of some cancer cells, and several tar-
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Figure 1. Number of new publications for autoantigen and autoantibodies from 1945 to 2016. The search was performed using the keyword of either (A)
autoantigen or (B) autoantibody in PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) on July 9, 2016; the total number was calculated using the sum of
publications for autoantigen and autoantibody, respectively.
geted therapies directly against HER2 have been employed
to treat breast and stomach cancers, i.e. trastuzumab (Her-
ceptin®) (17).
However, the information of previously identified AAgs
is dispersed in thousands of published papers, and the sys-
tematic investigation of human AAgs is hampered due to
unavailability of a comprehensive human AAg collection.
To address this need, Wang et al. constructed a Human Po-
tential Tumor Associated Antigen (HPtaa) database that
collected 3518 potential tumor antigens identified by in
silico computing (http://www.hptaa.org) based on tumor-
specific expression, coding capacity, chromosomal location,
subcellular location and the knowledge of gene function
(18). Almeida et al. constructed a cancer testis antigen
database, CTdatabase (http://www.cta.lncc.br), which con-
tains 276 genes that were compiled manually from the lit-
erature and computational prediction (19). However, these
two databases only cover a small fraction of the published
AAgs and their inclusion of predicted but not documented
AAgs can be confusing (Figure 2B).
We have built an AAgAtlas database using text-mining
and manual curation with the aim to provide a comprehen-
sive AAg repository that supports basic and translational
studies. We extracted 45 830 AAg-related abstracts and 94
313 sentences from PubMed by the keywords of either ‘au-
toantigen’ or ‘autoantibody’ or their lexical variants, which
were further refined to 25 520 abstracts, 43 253 sentences
and 3984 candidates by bio-entity recognizer based on the
Protein Ontology (20,21). A total of 1126 genes were se-
lected as human AAgs after three rounds of manual cura-
tion, and 1071 associated human diseases were identified
based on the Human Disease Oncology (22) accordingly.
AAgAtlas database 1.0 provides a user-friendly interface to
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Figure 2. Construction of AAgAtlas 1.0 database. (A) The workflow of AAgAtlas database construction; (B) Comparison of human antigens between
AAgAtlas and CTDatabase.
conveniently browse, retrieve and download the list of hu-
man AAgs and their related diseases.
DATA COLLECTION AND MANUAL CURATION
Our data collection relied on the text mining of AAg-related
PubMed abstracts. Bio-entity recognition and extraction
from these abstracts for human AAg candidates were per-
formed by our custom developed ontology-based bio-entity
recognizer. After evaluation against the CRAFT corpus for
gene/protein recognition based on Protein Ontology (PR)
(20,21), the F-measure, the point where precision and recall
are equal(23), of our recognition tool is 0.845, which is on
a par with that of current state-of-the-art biomedical anno-
tation system, BeCAS, 0.76 (24).
We compiled a list of human AAgs together with their
related diseases as well as the evidence from PubMed ab-
stract using the following three steps. All PubMed abstracts
were fetched through the NCBI E-utilities API (25) and
the AAg-related abstracts were extracted by our bio-entity
recognizer with the keywords of either ‘autoantigen’ or
‘autoantibody’ or their lexical variants like ‘auto-antigen’,
‘auto antigen’, ‘autoantigens’,‘ auto-antigens’, ‘auto anti-
gens’, ‘auto-antibody’, ‘auto antibody’, ’autoantibodies’,
‘auto-antibodies’ or ‘autoantibodies’. 45,830 AAg-related
abstracts and 94,313 sentences were obtained.
Then, a dictionary of human gene/protein names and
synonyms was built by integrating all terms and their cor-
respondent synonyms from the Protein Ontology. These
were mapped to all the official symbols of human genes
provide by HUGO Gene Nomenclature Committee (www.
genenames.org/) (26). The human genes that were recog-
nized and extracted from the previously generated set of
sentences were considered as candidate AAgs.
All 3984 candidates from 25 520 original abstracts and
43 253 evidence sentences in which the gene and keyword
co-occurred were validated through three rounds of manual
curation. First, all sentences with AAg names were checked
and selected by two experienced researchers independently;
second, these selected sentences were submitted to an inter-
nal review, in which all AAg names were manually reviewed
and approved one by one by a reviewer panel consisting of
three experts; third, we asked all co-authors to randomly
check AAgs from our website to make sure that all genes
loaded into our database are bona fide AAgs.
Disease terms were extracted from the abstracts by our
recognition tool based on the Human Disease Ontology
(22,27). The logic relation type between child disease term
node and parent node in the ontology has been taken into
consideration as in NCBOAnnotator (28), i.e. if a child dis-
ease term is associated with an AAg, then its Human Dis-
ease Ontology parent disease terms are supposed to be as-
sociated as well. Associations between AAg genes/proteins
and human disease terms were generated by sentence-level
co-occurrence and scored by co-occurrence count. All ex-
tracted AAg genes/proteins, human disease terms as well
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Figure 3. Analysis of human autoantigen’s protein classes and major related diseases. (A) Classification of all human autoantigens using PANTHER
(http://pantherdb.org/) (42). (B) Major diseases associated with human autoantigens. The diseases containing more than 100 human autoantigens were
selected.
as their associations and evidence abstracts with biomed-
ical keywords highlighted were stored in the our database
for user query and navigation (Figure 2A).
We obtained 1126 humanAAgs and 1071 related diseases
and constructed the human AAg database (AAgAtlas 1.0
database) (Figures 2-4). All evidence sentences that have
been manually curated for AAgs are regarded as validated
evidence and included on the top of eachAAgpage (Supple-
mentary Figure S1). Considering all AAgs and their related
diseases were documented from previous publications that
might not be fully validated, we added a simple community
curation function to the evidence phrases with which the
users can easily provide their feedback by simply clicking
the green ‘Yes’ or red ‘No’ button after login as registered
users (Supplementary Figure S1 and Figure S2). With this
function, the users can confirm or reject that the evidence
phrase has the correct AAg and related disease.
DATA SEARCH AND NAVIGATION
We provide a user-friendly web interface that facilitates
searching, exploring information and updating the AAgAt-
las 1.0 database (http://biokb.ncpsb.org/aagatlas/) (Figure
4). The website interface comprises six sections including
‘Home’, ‘Browse & Download’, ‘FAQ’, ‘Contact’, ‘Feed-
back’ and ‘Log in’. From the ‘Home’ page, the users can
see the introduction to AAgAtlas 1.0 database and search
for their gene or disease of interest. By selecting ‘Browse &
Download’ in the navigation bar, the complete list of human
AAgs, their related diseases and supporting evidence can
be browsed and downloaded in one page. From the ‘FAQ’
page, the users can see the general questions and answers.
From the ‘Feedback’ page, the users can submit new genes
to our database manually. From the ‘Log in’ page, the users
can make the registration and start do the manual curation
on our website. Our database will be updated periodically in
future according to these information provided by the users.
Two query approaches are provided for searching AAg:
query by gene symbol and query by disease term.
Query by gene symbol
For the query by gene symbol, the users can enter an NCBI
Entrez gene symbol in the ‘Gene Symbol’ search box, and a
drop downmenuwill provide auto-completed gene symbols
present in the AAgAtlas (Supplementary Figure S1). After
selecting one of them and clicking the ‘Search’ button, the
search engine will return the queried results containing a
table showing the gene name, related diseases as well as the
supporting literature evidence. By clicking the hyperlink of
the gene symbol for an individual AAg in the ‘Gene’ col-
umn, users can obtain the basic information for the AAg
gene and the cross references to external databases (i.e. En-
sembl (29), NCBI Gene (30), UniProtKB (31), neXtProt
(32) and Antibodypedia (33)).
For example, p53 is perhaps one of the most famous
AAgwhose antibodies are frequently up-regulated in serum
or plasma of cancer patients (34). Here, we searched our
database with ‘TP53′ and the results revealed that p53might
be involved into more than one hundred different diseases
such as liver cancer, neck cancer, lymphoma and rheumatic
disease, etc (Supplementary Table S1). This result empha-
sizes the role of p53 in the development of different human
diseases.
Query by disease term
For the query by disease term, the user can enter a dis-
ease term in the ‘Disease Term’ search box, and a drop
down menu will provide disease terms that were extracted
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Figure 4. Screenshot of the AAgAtlas database website. The website comprises ‘Home’, ‘Browse & Download’, ‘FAQ’, ‘Contact’, ‘Feedback’ and ‘Log in’
sections. From the ‘Home’ page, the users can see the introduction of AAgAtlas 1.0 database and search for the gene or disease of their interest. From
the ‘Browse & Download’, the users can see and download the human AAgs, their related diseases and supporting evidences. The ‘FAQ’ page shows the
general questions and answers. The ‘Contact’ page shows the emails of web managers that are used for further communications. With the ‘Feedback’ page,
the users can submit new genes to our database manually. From the ‘Log in’ page, the users can make the registration and start do the manual curation on
our website. Our database will be updated periodically according to these information provided by the users.
with AAgs from literature, i.e. Breast carcinoma (Supple-
mentary Figure S2). After selecting one of them and click-
ing the ‘Search’ button, the search engine will return the
queried results containing a table showing the disease name,
related AAg genes, and the supporting literature evidence.
When the user clicks the small triangle on the head of each
table column, the results in the table will be resorted in
ascending/descending order for that column. The users can
also input words or select a term in the drop list of the text
box to filter listed genes or diseases from the results by sub-
string match. In addition, when the users click the number
of the evidence abstracts or sentences, a table containing
gene, disease, PubMed ID, evidence and manual validation
information will be displayed. The users can click the hy-
perlink of evidence to see the original abstract in which the
key words, i.e. gene and disease names, are also highlighted.
For example, as the sixth most common cancer and the
second leading cause of cancer death in the world, liver can-
cer is closely associated with the body’s immune system that
could either evacuate the abnormally growing cells or at-
tack healthy liver cells causing inflammation and liver dam-
age (35,36). We searched our database with ‘Liver cancer’
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Figure 5. Bioinformatics analysis of the human autoantigens associated with liver cancer. (A) Biological and pathway analysis using Reactome (http:
//www.reactome.org/). (B) Protein class analysis using PANTHER (http://pantherdb.org/) (42).
and found 53AAg genes. The analysis withReactome (http:
//www.reactome.org/) (37) reveals that these genes partici-
pate in the DNA repair, signal transduction, gene expres-
sion, immune system, metabolism of proteins, cell cycle,
programmed cell death and cellular responses to stress (Fig-
ure 5A, Supplementary Table S2 and S3). The protein class
analysis indicates that these AAgs are the proteins belong-
ing to nucleic acid binding, enzymes, cytoskeletal protein,
receptor, signaling molecule and transcription factors, etc.
(Figure 5B). The results align well with previously reported
results on liver cancer studies (38) and suggest that AAgs
might be active proteins in the development of human dis-
ease.
DATABASE IMPLEMENTATION AND DESIGN
AAgAtlas database runs entirely on open software
(MySQL database server, Apache web server with the
interface written in PHP, Ubuntu Linux operating system).
Python scripts were written for data collection and process-
ing and text mining. The web interface is available online
at http://biokb.ncpsb.org/aagatlas/.
DISCUSSION AND CONCLUSION
Since the first AAg paper appeared in 1945, more than 120
000 papers have been published and 1000 AAgs have been
identified. Some of them have been shown to be important
regulators or biomarkers in both healthy people and pa-
tients of different diseases. Reports of these AAgs occur in
thousands of paper scattered through the literature (Fig-
ure 1) and construction of a systematic database for AAgs
would be valuable to study the generation, evolution and
function of AAb as well as to elucidate the mechanism of
our human immune system inmaintaining homeostasis and
evacuating abnormal growing cells.
In this work, we searched and extracted the abstracts
of all publications from Pubmed with ‘Autoantibody’, ‘Au-
toantigen’ and their synonyms using text mining and a
self-developed ontology-based bio-entity recognizer. We
evaluated our data set against the CRAFT corpus for
gene/protein recognition based on Protein Ontology (PR)
(20,21), and the results indicate that the F-measure (0.835)
of our recognition tool is comparable to that of the state-of-
art biomedical annotation system, BeCAS (0.76) (24). We
Nucleic Acids Research, 2017, Vol. 45, Database issue D775
compiled a list of 1126 human AAgs followed after a se-
ries of manual curation and constructed the AAgAtlas 1.0
database (Figures 2-4). We compared AAgAtlas 1.0 (1126
antigens) database to CTdatabase (276 antigens) and found
that only 26 antigens overlapped (Figure 2B). This might be
due to that many antigens from CTdatabase were selected
based on computational prediction (19). Thewebsite ofHP-
taa database is not available and thus the comparison to
AAgAtlas was not performed. The results here suggest that
AAgAtlas 1.0 database is the largest collection of human
AAgs to date.
In addition, the comprehensive collection of AAgAtlas
1.0 database allows us to have an overview of human AAgs’
protein classes and their related diseases. The gene ontology
analysis reveals that the largest class of autoantigen proteins
is nucleic acid binding, followed by signalling molecule, hy-
drolase, cytoskeletal protein, receptor, enzyme modulator
and transcription factor (Figure 3A). The disease ontology
analysis results suggest that human AAg proteins are ac-
tively involved in major human diseases including immune
system, hypersensitivity reaction, musculoskeletal system
and cancer (Figure 3B). All these results demonstrate the
importance of our AAg collection and show the value of
AAgAtlas 1.0 database in human AAg studies.
However, several issues should be considered for AAgAt-
las 1.0 database. First, some AAgs in the full texts of the
literature are not shown in abstracts and might not be in-
cluded in our database. Currently there is no universal or
centralized system capable of screening full text articles (39),
especially for the journals frommost publishers that are not
freely available. The published abstracts are still the main
resource for text-mining to date (40). To obtain AAgs from
full text, we have to figure out a systematic plan to obtain
as many of these full-text papers as possible and extract
AAgs from them, which will be executed in the next ver-
sion of AAgAtlas database. Second, some AAbs recognize
the post-translational modifications instead of protein epi-
topes. In this work, all AAgs were selected based on the
proteins of AAb targeted regardless of post-translational
modifications (3). This may be due to the lack of high
throughput AAb screening platforms that display proteins
with modifications, although one was recently published
(41). Third, AAbs that recognize non protein biomolecules
such as lipids, DNA or small molecules (3), were not con-
sidered in our database. Fourth, our curation process only
confirmed that authors reported them as AAg and did not
validate the supporting data from the experiments. To ad-
dress this issue, we added a manual curation function to the
end of each evidence phase with which the users can sim-
ply click the green ‘Yes’ or red ‘No’ button to confirm or
deny our evidence (Supplementary Figure S1 and Figure
S2). Our database system will be updated periodically.
In conclusion, we identified 1126 AAgs, covering ∼5%
of the human genome, and 1071 related human diseases by
text mining and manual curation. We built the AAgAtlas
1.0 database and website (http://biokb.ncpsb.org/aagatlas/)
that is freely available to the scientific community to browse,
search and download. It also provides a simple community
curation interface for future enhancements. We believe it
will be a valuable resource for scientific community to in-
vestigate the functions of human AAgs and their related
diseases in the future.
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Supplementary Data are available at NAR Online.
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